To: **CAHAN San Diego Participants**
Date: **February 26, 2025**
From: **Public Health Services**

Health Advisory: Adverse Events Following Receipt of Injectable Ceftriaxone

Key Messages

- Reports of serious adverse events, including deaths, following receipt of injectable ceftriaxone are currently under investigation by CDC and state and local health departments.
- To date, these events have not been associated with a single product manufacturer or lot, nor has a definitive causal link to ceftriaxone been established.
- Providers should report adverse events following the use of injectable ceftriaxone that meet specific criteria and occurred after September 1, 2024, to CDC.

Situation

The Centers for Disease Control and Prevention (CDC), in collaboration with state and local health departments, is investigating reports of serious adverse events, including deaths, following receipt of injectable ceftriaxone. To date, events have not been associated with a single product manufacturer or lot, and a definitive causal link to ceftriaxone has not been established. CDC is requesting reports of serious adverse events following the administration of ceftriaxone to assist with the ongoing investigation.

Actions Requested

1. ***Review*** post-injection monitoring protocols in your setting to verify adverse events are promptly detected and reported.
2. ***Consider*** retaining open ceftriaxone product administered to the patient, if possible, should an event be detected in real time. Further instruction may be given by CDC. At this time, there is no recommendation to sequester unused product or withhold ceftriaxone administration for patients that need it.
3. ***Report*** adverse events that meet the following criteria, occurring after September 1, 2024:
   - **a.** Occurred within 6 hours after receipt of injectable* ceftriaxone in a non-intensive care unit (ICU) setting, and
   - **b.** Resulted in death or required cardiopulmonary resuscitation**, and
   - **c.** Not attributed by the treating provider(s) to a cause other than ceftriaxone administration***

     **including both intramuscular and intravenous routes of administration*

     ***cardiopulmonary resuscitation defined as the use of chest compressions and mechanical ventilation or provision of rescue breaths to maintain circulatory flow and oxygenation during cardiac arrest*

     ****such as known infection, other underlying medical condition, or exposure to a medication or medical product other than ceftriaxone*
4. ***Report*** to the Epidemiology Unit of reports of adverse events following Ceftriaxone injection by calling 619-692-8499 (Monday-Friday 8 AM-5 PM). Reports will be forwarded to CDC's Division of Healthcare Quality Promotion and to the California Department of Public Health Healthcare-Associated Infections (HAI) Program. Healthcare

providers should also report serious adverse events that might be associated with a medical product to the Food and Drug Administration's (FDA) MedWatch Program and to the product manufacturer.

Thank you for your participation.

CAHAN San Diego
County of San Diego Health & Human Services Agency
Epidemiology and Immunization Services Branch
Phone: (619) 692-8499; Fax: (858) 715-6458
Urgent Phone for pm/weekends/holidays: (858) 565-5255
E-mail: cahan@sdcounty.ca.gov
Secure Website: http://cahan.ca.gov
Public Website: http://www.cahansandiego.com